NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued development of PrimeC's multi-target approach in Alzheimer's diseaseCAMBRIDGE, Mass., June 25, 2026 /PRNewswire/ –…

Read the full release →

News provided by PR Newswire.